Clinical Trials Logo

Filter by:
NCT ID: NCT05514665 Not yet recruiting - Clinical trials for Hypoxic-Ischemic Encephalopathy

Functional Imaging of Baby Brains

FIBB
Start date: March 2024
Phase:
Study type: Observational

Infants are at risk of developing motor and cognitive neurodevelopmental disabilities as a sequelae to hypoxic-ischemic brain injury during the perinatal period. It is an ongoing challenge to predict the severity and extent of future developmental impairment during the neonatal period. This study will help test the feasibility of conducting a large-scale study that evaluates the role of diffuse optical tomography as a bedside neuroimaging tool in complementing the prognostic value of conventional and diffusion weighted MRI for predicting neurodevelopmental outcome in neonates with perinatal hypoxic-ischemic brain injury.

NCT ID: NCT05514548 Active, not recruiting - Clinical trials for Diabetic Kidney Disease

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Start date: October 19, 2022
Phase: Phase 2
Study type: Interventional

The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus

NCT ID: NCT05514483 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

5-HT3 Receptor Antagonist and Respiratory Drive in Patients With ARDS

DRIVE
Start date: November 10, 2022
Phase: Phase 4
Study type: Interventional

This is a pilot study aimed at acquiring primary physiological data, describing and estimating the effects of a 5-HT3 receptor antagonist (ondansetron) on respiratory drive in patients with acute respiratory distress syndrome (ARDS). The results of this study will determine the interest and feasibility of assessing the clinical applications of ondansetron in reducing patient self-inflicted lung injury (P-SILI) in ARDS, in subsequent studies.

NCT ID: NCT05514444 Recruiting - Neoplasms Clinical Trials

Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)

Start date: September 25, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of MK-4464 as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.

NCT ID: NCT05514431 Enrolling by invitation - Anesthesia Clinical Trials

Conversion of Labor Analgesia for Intrapartum Cesarean Delivery: DPE v CSE v Epidural

Start date: February 1, 2017
Phase:
Study type: Observational

As the dural puncture epidural (DPE) is increasing in popularity for labor analgesia, it is important to understand how it impacts outcomes in parturients. Prior studies have found epidural catheters placed via the combined-spinal epidural technique have greater success at surgical conversion for cesarean delivery than catheters placed via traditional techniques. The investigators aim to determine if epidural catheters placed by a DPE technique will also have an increased successful conversion for surgical anesthesia by conducting a retrospective review of all CD during the study period. If an association is found, this could be another benefit of DPE for labor analgesia.

NCT ID: NCT05514093 Active, not recruiting - Clinical trials for Post-traumatic Stress Disorder

Beyond Silence: Advancing E-mental Health Solutions to Support Canadian Healthcare Workers

Start date: November 1, 2022
Phase:
Study type: Observational

The purpose of this project is to scale implementation and evaluation of an m-health app designed to promote early intervention and mental health support for frontline healthcare workers to reduce their risk of post-traumatic stress disorder (PTSD) and/or the mental health impact of the COVID-19 pandemic. Beyond Silence has received an additional year of funding to scale implementation across 4-6 additional healthcare organizations.

NCT ID: NCT05514080 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study to Evaluate Eli Lilly's Insulin Dosing Algorithm to Control Glycemia in Insulin-treated Adults With Type 2 Diabetes

Start date: December 6, 2019
Phase: N/A
Study type: Interventional

The objective of this study is to generate preliminary data in an inpatient setting to help optimize an insulin dosing logic (that decides how much to deliver insulin) for Eli Lilly's system.

NCT ID: NCT05514054 Recruiting - Breast Neoplasms Clinical Trials

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

EMBER-4
Start date: October 4, 2022
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.

NCT ID: NCT05513560 Recruiting - Long COVID Clinical Trials

RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine

RECLAIM
Start date: May 31, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The researchers propose to develop a Canada-wide, adaptive randomized clinical platform trial to assess the effectiveness of various interventions in patients with lingering symptoms of COVID-19 ("Long COVID"). Participants will be randomized initially to 1 of 3 arms, including placebo (control) and 2 interventions. Because this is an adaptive trial, arms can be dropped if found to be ineffective and new arms can be added. Interventions will last for 2 months and participants will be followed for an additional 4 months (6 months total). Approximately 800-1000 patients with Long COVID will be recruited across Canada. Results from this trial will accelerate the availability of high-quality, real-time evidence and solutions to enable Canada to improve the clinical care of patients with Long COVID.

NCT ID: NCT05513326 Recruiting - Spinal Stenosis Clinical Trials

Effectiveness of a 6-week Specific Rehabilitation Program on Walking Capacity in Patients With Lumbar Spinal Stenosis

Start date: January 26, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to determine the effectiveness of a 6-week specific rehabilitation program combining education and exercises on walking capacity in patients with LSS causing NC. The intervention group will receive standardized education and specific exercises while the control group will only receive standardized education. The program in both groups will last for 6 weeks with 4 evaluation timepoints (baseline, week 2, week 4 and post-intervention assessment). The primary outcomes will be walking capacity measured with the Self-Paced Walking Test and the secondary outcomes will be back and leg pain intensity, LSS-related disability, self-efficacy, level of physical activity, anxiety and depression, physical activity level, gait pattern characteristics, balance, and global perceived change.